FTD/TPI plus oxaliplatin well-tolerated but not broadly effective as treatment for esophageal cancer

A recent research effort led by Sarbajit Mukherjee, MD, MS, Assistant Professor of Oncology at Roswell Park Comprehensive Cancer Center, demonstrated that a new chemotherapy combination—trifluridine/tipiracil (FTD/TPI) and oxaliplatin—is well tolerated and has activity among patients with esophageal cancer.

Leave A Comment

Your email address will not be published. Required fields are marked *